ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.

被引：0
|
作者：
Sands, Jacob
Mandrekar, Sumithra J.
Oxnard, Geoffrey R.
Kozono, David E.
Hillman, Shauna L.
Dahlberg, Suzanne Eleanor
Sun, Zhuoxin
Chaft, Jamie E.
Govindan, Ramaswamy
Gerber, David E.
Gray, Jhanelle Elaine
Malik, Shakun M.
Mooney, Margaret M.
Janne, Pasi A.
Vokes, Everett E.
Kelly, Karen
Ramalingam, Suresh S.
Stinchcombe, Tom
机构：
[1] Lahey Hosp & Med Ctr, Boston, MA USA
[2] Mayo Clin, Rochester, MN USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] IBCSG Stat Ctr, Boston, MA USA
[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[6] Washington Univ, Sch Med, St Louis, MO USA
[7] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[8] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[9] NCI, Rockville, MD USA
[10] Univ Chicago Med, Dept Med, Sect Hematol Oncol, Chicago, IL USA
[11] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA 95817 USA
[12] Emory Univ Hosp, Winship Canc Inst, 1364 Clifton Rd NE, Atlanta, GA 30322 USA
[13] Duke Canc Inst, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9077
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Combination Immunotherapy for High-Risk Resected and Metastatic Melanoma Patients
    Riker, Adam I.
    Rossi, Gabriela R.
    Masih, Prerna
    Alsfeld, L. C.
    Denham, Fiona
    Tennant, Lucinda
    Ramsey, W. Jay
    Vahanian, Nicholas N.
    Link, Charles J.
    OCHSNER JOURNAL, 2014, 14 (02): : 164 - 174
  • [22] Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis
    Lattanzi, Michael
    Han, Joseph
    Moran, Una
    Utter, Kierstin
    Tchack, Jeremy
    Sabado, Rachel Lubong
    Berman, Russell
    Shapiro, Richard
    Huang, Hsin-Hui
    Osman, Iman
    Bhardwaj, Nina
    Pavlick, Anna C.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [23] Update on adjuvant therapy in completely resected NSCLC patients
    Lim, Jeong Uk
    Yeo, Chang Dong
    THORACIC CANCER, 2022, 13 (03) : 277 - 283
  • [24] Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)
    Sands, Jacob M.
    Mandrekar, Sumithra J.
    Kozono, David
    Oxnard, Geoffrey R.
    Hillman, Shauna L.
    Wigle, Dennis A.
    Govindan, Ramaswamy
    Carlisle, Jennifer
    Gray, Jhanelle
    Salama, Joseph K.
    Raez, Luis
    Ganti, Apar
    Foster, Nathan
    Malik, Shakun
    Bradley, Jeffrey
    Kelly, Karen
    Ramalingam, Suresh S.
    Stinchcombe, Thomas E.
    IMMUNOTHERAPY, 2021, 13 (09) : 727 - 734
  • [25] Initiation of targeted therapy based on ctDNA only in metastatic NSCLC.
    Alvarez, Jean Gabriel Bustamante
    Dittmar, Kristin
    Janse, Sarah A.
    Kiourtsis, Stephanie
    Owen, Dwight Hall
    Bertino, Erin Marie
    He, Kai
    Carbone, David Paul
    Otterson, Gregory Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] The Role of Targeted Therapy in the Management of High-Risk Resected Kidney Cancer What Have We Learned and How Will It Inform Future Adjuvant Trials
    Brown, Landon C.
    Zhang, Tian
    George, Daniel J.
    CANCER JOURNAL, 2020, 26 (05): : 376 - 381
  • [27] Adjuvant Imatinib in High-Risk Resected GIST: Merely Delaying the Inevitable?
    Sutton, T. L.
    Walker, B. S.
    Billingsley, K. G.
    Corless, C.
    Sheppard, B. C.
    Heinrich, M.
    Mayo, S. C.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 1) : S127 - S128
  • [28] A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma
    Messori, A
    Becagli, P
    Trippoli, S
    Tendi, E
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (09) : 1373 - 1379
  • [29] Utilization and Survival Benefit of Adjuvant Immunotherapy in Resected High-Risk Stage II Melanoma: A National Cancer Database Analysis
    Wong, W. G.
    Olecki, E.
    Stahl, K.
    Holguin, R. Perez
    Pameijer, C.
    Shen, C.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 1) : S27 - S27
  • [30] Adjuvant Systemic Therapy for High-Risk Melanoma
    Sonia Cohen
    Kenneth K. Tanabe
    Annals of Surgical Oncology, 2023, 30 : 2568 - 2569
12345